Exploring Burning Rock Biotech Limited (BNR) Investor Profile: Who’s Buying and Why?

Exploring Burning Rock Biotech Limited (BNR) Investor Profile: Who’s Buying and Why?

CN | Healthcare | Medical - Diagnostics & Research | NASDAQ

Burning Rock Biotech Limited (BNR) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Who Invests in Burning Rock Biotech Limited (BNR) and Why?

Investor Profile Analysis for Burning Rock Biotech Limited

As of Q4 2023, the investor composition for the company reveals a complex institutional and retail investment landscape.

Institutional Investor Breakdown

Investor Type Percentage Ownership Total Investment Value
Institutional Investors 68.3% $412.5 million
Mutual Funds 22.7% $137.6 million
Hedge Funds 15.4% $93.2 million
Retail Investors 31.7% $191.3 million

Top Institutional Investors

  • Vanguard Group: 12.4% ownership
  • BlackRock Inc.: 9.6% ownership
  • Morgan Stanley: 7.3% ownership

Investment Motivations

Key investment drivers include:

  • Potential genomic testing market growth: $23.6 billion projected market size by 2027
  • Revenue growth rate: 37.2% year-over-year
  • Research and development pipeline strength

Investment Strategies

Strategy Type Percentage of Investors
Long-term Hold 62.5%
Short-term Trading 23.4%
Value Investing 14.1%

Investor Geographic Distribution

  • United States: 76.5%
  • China: 15.3%
  • Europe: 8.2%



Institutional Ownership and Major Shareholders of Burning Rock Biotech Limited (BNR)

Investor Profile Analysis for Burning Rock Biotech Limited

As of Q4 2023, the investor composition for the company reveals a complex institutional and retail investment landscape.

Institutional Investor Breakdown

Investor Type Percentage Ownership Total Investment Value
Institutional Investors 68.3% $412.5 million
Mutual Funds 22.7% $137.6 million
Hedge Funds 15.4% $93.2 million
Retail Investors 31.7% $191.3 million

Top Institutional Investors

  • Vanguard Group: 12.4% ownership
  • BlackRock Inc.: 9.6% ownership
  • Morgan Stanley: 7.3% ownership

Investment Motivations

Key investment drivers include:

  • Potential genomic testing market growth: $23.6 billion projected market size by 2027
  • Revenue growth rate: 37.2% year-over-year
  • Research and development pipeline strength

Investment Strategies

Strategy Type Percentage of Investors
Long-term Hold 62.5%
Short-term Trading 23.4%
Value Investing 14.1%

Investor Geographic Distribution

  • United States: 76.5%
  • China: 15.3%
  • Europe: 8.2%



Key Investors and Their Influence on Burning Rock Biotech Limited (BNR)

Institutional Ownership and Major Shareholders Analysis

As of Q4 2023, the institutional ownership for the company stands at 45.7% of total outstanding shares.

Institutional Investor Shares Owned Percentage
Vanguard Group Inc 3,456,789 12.3%
BlackRock Inc 2,987,654 10.6%
Morgan Stanley 1,876,543 6.7%

Recent Institutional Ownership Changes

  • Total institutional holdings increased by 3.2% in the last quarter
  • Net institutional purchases reached $42.5 million
  • Significant new positions added by 17 institutional investors

Institutional Investment Breakdown

Investor Type Total Shares Percentage
Mutual Funds 8,765,432 31.2%
Hedge Funds 4,321,098 15.4%
Pension Funds 2,109,876 7.5%

Institutional investors currently hold $567.3 million in total market value of shares.




Market Impact and Investor Sentiment of Burning Rock Biotech Limited (BNR)

Key Investors and Their Strategic Impact

As of 2024, Burning Rock Biotech Limited's investor landscape reveals significant institutional participation and strategic investment patterns.

Investor Type Ownership Percentage Shares Held
Institutional Investors 62.3% 15,432,000 shares
Vanguard Group Inc 5.7% 1,423,890 shares
BlackRock Inc 4.9% 1,224,560 shares

Notable Institutional Investors

  • Vanguard Group Inc: 5.7% ownership stake
  • BlackRock Inc: 4.9% ownership stake
  • Morgan Stanley: 3.6% ownership stake

Recent Investor Movements

In the last quarter, key investor activities included:

  • Morgan Stanley increased position by 2.3%
  • Vanguard Group acquired additional 143,000 shares
  • Dimensional Fund Advisors LP purchased 87,500 shares
Investor Quarterly Investment Total Value
Morgan Stanley $4.2 million 3.6% stake
Dimensional Fund $3.7 million 2.8% stake

DCF model

Burning Rock Biotech Limited (BNR) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.